Repligen (NASDAQ:RGEN) Sees Strong Trading Volume – Still a Buy?

Shares of Repligen Corporation (NASDAQ:RGEN) saw strong trading volume on Wednesday . 563,554 shares were traded during trading, a decline of 42% from the previous session’s volume of 971,611 shares.The stock last traded at $140.69 and had previously closed at $136.99.

Key Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: The deal should strengthen Repligen’s position in cell therapy by adding BioLife’s biopreservation media and cell processing tools, expanding its addressable market and customer offering. Article Title
• Positive Sentiment: Management said the transaction should be accretive to adjusted EPS by at least $0.05 in year one and $0.25 in year two, with at least $20 million in synergies in year one and $30 million in year two. Article Title
• Positive Sentiment: Preliminary Q2 results were also supportive, with Repligen expecting about 12% reported revenue growth and 13% organic growth, suggesting continued underlying business momentum. Article Title
• Neutral Sentiment: The merger is not expected to close until Q4 2026 and still needs regulatory and shareholder approvals, leaving some timing uncertainty. Article Title
• Negative Sentiment: The market may be reacting to dilution and integration concerns because the purchase is being funded with both cash and Repligen stock, while the acquired business adds execution risk if expected synergies do not materialize. Article Title

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RGEN shares. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 14th. Evercore reaffirmed an “outperform” rating and set a $160.00 target price on shares of Repligen in a report on Monday, July 6th. JPMorgan Chase & Co. decreased their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.36.

Repligen Stock Performance

The stock’s 50-day moving average price is $131.09 and its 200-day moving average price is $132.60. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.76 billion, a P/E ratio of 152.89, a P/E/G ratio of 2.70 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.25 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Repligen

Several hedge funds have recently made changes to their positions in RGEN. NewEdge Wealth LLC increased its holdings in shares of Repligen by 5.3% in the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 75 shares during the period. UMB Bank n.a. boosted its stake in Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 92 shares during the period. CANADA LIFE ASSURANCE Co boosted its stake in Repligen by 0.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after purchasing an additional 100 shares during the period. Coldstream Capital Management Inc. grew its position in Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.